SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma

Article ID	Journal	Published Year	Pages	File Type
6175243	European Urology	2015	4 Pages	PDF

Abstract

The addition of sunitinib to standard cisplatin and gemcitabine chemotherapy was poorly tolerated and did not improve outcomes in advanced urothelial carcinoma. Treatment delivery was limited by myelotoxicity.

Keywords

First-line treatment Sunitinib Phase 2 Clinical trial

Related Topics

Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health

Preview

SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma

Authors

Thomas Geldart, John Chester, Angela Casbard, Simon Crabb, Tony Elliott, Andrew Protheroe, Robert A. Huddart, Graham Mead, Jim Barber, Robert J. Jones, Joanna Smith, Robert Cowles, Jessica Evans, Gareth Griffiths,